Notre groupe organise plus de 3 000 séries de conférences Événements chaque année aux États-Unis, en Europe et en Europe. Asie avec le soutien de 1 000 autres Sociétés scientifiques et publie plus de 700 Open Access Revues qui contiennent plus de 50 000 personnalités éminentes, des scientifiques réputés en tant que membres du comité de rédaction.

Les revues en libre accès gagnent plus de lecteurs et de citations
700 revues et 15 000 000 de lecteurs Chaque revue attire plus de 25 000 lecteurs

Abstrait

Effects of Antiangiogenic Agent Bevacizumab on Over Cancer Cell Culture (Ovcar-3) Alone and Combined with Classic Chemotherapeutics

Ozlem Ozgür Gursoy, Ceren Yildiz Eren, Hulusi Goktug Gurer, Ayşe Tansu Koparal, Sabit Sinan Ozalp

Background: Cancer is an important problem that has serious effects on the quality of life. Despite advances in diagnosis, it still affects millions of people. Ovarian cancer is the most common cause of gynecological cancer deaths; it has a very important place in gynecological oncology. Combination therapy is a treatment method that combines more than one agent used in treatment. Today it is one of the most important weapons in cancer treatment.

Methods: In this study, the aim was to examine the sole and combined effects of classical chemotherapeutics and Bevacizumab on Ovcar-3 cells in vitro.

Results: To determine the effects of classical chemotherapeutics, and Bevacizumab on Ovcar-3 cells, MTT, DAPI staining, caspase-3 and real-time PCR analyses was performed. In the light of the data obtained from the MTT results, it was determined that bevacizumab did not have any effect on ovcar-3 cells, so DAPI staining and caspase-3 analyses were not conducted with this substance. It was observed that the combination of paclitaxel 2.5 nM+carboplatin 100 μM caused a decrease on IRS, COX-2 and VEGF gene levels. Bevacizumab was not included in the analysis as it was found to have no effect on ovcar-3 cells.

Conclusion: In this study, classical chemotherapeutics sole and in combination showed significant anticancer effects in MTT, DAPI Staining, Caspase-3 and Real-Time PCR analyses in Ovcar-3 cancer cell lines. However, the same effect was not observed with Bevacizumab and this is different from some results in the literature. Researching this subject with new studies will contribute to the literature.

Avertissement: Ce résumé a été traduit à l'aide d'outils d'intelligence artificielle et n'a pas encore été examiné ni vérifié.